Verified ComparisonLast updated: 21 April 2026
Retatrutide vs Tirzepatide
Retatrutide adds glucagon receptor agonism on top of GIP/GLP-1. The clinical question is whether the additional mechanism adds durable benefit beyond the dual agonist class.
Retatrutide
Metabolic
4.8/ 5
A+
Tirzepatide
Metabolic
4.6/ 5
A
Editor's note
Retatrutide shows higher reported weight loss in available trials. Tirzepatide has approval and longer human follow-up.
| Criterion | Retatrutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 + GIP + glucagon | GLP-1 + GIP |
| Weight loss in trials | Highest reported | Robust |
| Regulatory status (AU) | Investigational | Approved |
| Long-term safety data | Limited | Accumulating |
Frequently asked questions
Tirzepatide is approved in Australia. Retatrutide is not.
Want to read the full reviews?